Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-05-06T06:56:46.524Z Has data issue: false hasContentIssue false

A review of the safety of paroxetine

Published online by Cambridge University Press:  16 April 2020

SA Montgomery*
Affiliation:
Academic Department of Psychiatry, St Mary's Hospital, London, UK
Get access

Summary

The tolerability and safety of treatment with paroxetine have been assessed by analysis of a clinical trial database that extends to 4126 patients treated with paroxetine, 1954 patients on active control, and 625 placebo patients. A total of 451 patients were exposed to paroxetine for periods of 1 or more years. Paroxetine was generally better tolerated than active control and was associated with a lower frequency of manic reactions in bipolar patients and fewer seizures than active control. Paroxetine appears to offer a differential advantage in reducing suicidal thoughts; the number of suicides and attempted suicides per patient exposure year were lower for paroxetine than for other antidepressants or placebo.

Type
Research Article
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bignamini, ARapisarda, V (1992) A double-blind study of paroxetine and amitriptyline in depressed outpatients Int Clin Psychopharmacol 6 (suppl 4), 3741CrossRefGoogle ScholarPubMed
Cassidy, SHenry, J (1987) Fatal toxicity of antidepressant drugs in overdose Br Med J 295, 10211024CrossRefGoogle ScholarPubMed
Dillier, N (1982) Worldwide clinical experience with Ludiomil Act Nerv Super (Praha) 24, 4052Google ScholarPubMed
Dunbar, GCCohn, JBFabre, LFFeighner, JPFieve, RRMendels, JShrivastava, RK (1991) A comparison of paroxetine, imipramine and placebo in depressed outpatients Br J Psychiatry 159, 394398CrossRefGoogle Scholar
Feighner, JPBoyer, WF (1989) Paroxetine in the treatment of depression: a comparison with imipramine and placebo Acta Psychiatr Stand 80 (suppl 350), 125129CrossRefGoogle Scholar
Geltzer, J (1986) Limits to chemotherapy of depression Psychopathology 19, 108117CrossRefGoogle Scholar
Guillibert, EPelicier, YArchambault, JCChabannes, JPClerc, GDesvilles, MGuibert, MPagot, RPoisat, JLThobie, Y (1989) A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients Acta Psychiatr Scand 80 (suppl 350), 132134CrossRefGoogle Scholar
Hamilton, M (1967) Development of a rating scale for primary depressive illness Br J Soc Clin Psychol 6, 278296CrossRefGoogle ScholarPubMed
Hutchinson, DRTong, SMoon, CALVince, MClarke, A (1991) A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients Br J Clin Res 2, 4357Google Scholar
Jenner, PN (1992) Paroxetine: an overview of dosage, tolerability, and safety Int Clin Psychopharmacol 6 (suppl 4), 6980CrossRefGoogle ScholarPubMed
Johnson, AM (1991) The comparative efficacy of selective serotonin reuptake inhibitors in animalsIn: Selective Serotonin Reuptake Inhibitors. Perspectives in Psychiatry Vol 1 (Feighner, JPBoyer, WF eds). Wiley and Sons: Chichester, 3770Google Scholar
McCombs, JSNichol, MBStimmel, GLSclar, DABeasley, CMGross, LS (1990) The cost of antidepressant drug therapy failure: a study of antidepressant use patterns on a Medicaid population J Clin Psychiatry 51 (suppl), 6069Google ScholarPubMed
Montgomery, SA (1992) The advantages of paroxetine in different subgroups of depression Int Clin Psychopharmacol 6(suppl 4), 91100CrossRefGoogle ScholarPubMed
Montgomery, SAsberg, M (1979) A new depression rating scale designed to be sensitive to change Br J Psychiatry 134,382389CrossRefGoogle ScholarPubMed
Montgomery, SADunbar, G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression Int Clin Psychopharmacol 8, 189195CrossRefGoogle ScholarPubMed
Montgomery, SABaldwin, DFineberg, N (1990) Relative toxicity of antidepressants using reports independent of observer bias Neuropsychopharmacology 2, 580584CrossRefGoogle Scholar
Montgomery, SMcAuley, RRani, SRoy, DMontgomery, D (1981) A double blind comparison of zimelidine and amitriptyline in endogenous depression Acta Psychiatr Scand 68(suppl 290), 314327CrossRefGoogle Scholar
Muijen, MRoy, DSilverstone, TMehmet, AChristie, M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients Acta Psychiatr Scand 78, 384390CrossRefGoogle ScholarPubMed
Prien, RFKupfer, DJMansky, PASmall, JGTuason, VBVoss, CBJohnson, WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and lithium carbonate-imipramine combination Arch Gen Psychiatry 41,10961104CrossRefGoogle Scholar
Samuelian, JC (1991) A dose titration study comparing the efficacy and tolerability of paroxetine and clomipramine in elderly outpatients with moderate depression. Paper presented at 5th World Cong Biol Psychiatry, June 914Google Scholar
Tignol, JStoker, MJDunbar, GC (1992) Paroxetine in the treatment of melancholia and severe depression Int Clin Psychopharmacol 7, 9194Google ScholarPubMed
Wakelin, J (1988) The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? Adv Biol Psychiatry 17,7083CrossRefGoogle Scholar
Warrington, SJLewis, Y (1992) Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients Int Clin Psychopharmacol 6(suppl 4), 5964CrossRefGoogle ScholarPubMed
Wehr, TAGoodwin, FK (1987) Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 114, 14031411Google Scholar
Submit a response

Comments

No Comments have been published for this article.